Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moRIFABUTIN (rifabutin) by Pfizer is mechanism of action rifabutin inhibits dna-dependent rna polymerase in susceptible strains of escherichia coli and bacillus subtilis but not in mammalian cells. Approved for rifamycin antimycobacterial [epc], disseminated mycobacterium avium complex (mac) disease in patients with advanced hiv infection. First approved in 2014.
Drug data last refreshed 19h ago
Mechanism of Action Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammalian cells. In resistant strains of E. coli , rifabutin, like rifampin, did not inhibit this enzyme. It is not known whether rifabutin inhibits…
A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
Worked on RIFABUTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo